If you’ve been looking at natural, low-calorie sweeteners to add to your product line, you’ve probably stumbled on Brazzein— a protein-derived sweetener sourced from the fruit of the West African pentadiplandra brazzeana plant, known locally as “olekum” or “sweet gorilla nut” for its intensely sweet, fruit-forward flavor. As a supplier of Brazzein sweetener, I get questions about regulatory approval all the time, and the most common one? “Is Brazzein approved by the FDA?” It’s a fair question, especially as more food and beverage brands shift away from artificial sweeteners like aspartame and sucralose, both of which have faced public scrutiny in recent years. Brazzein Sweetener

Let’s cut through the noise: The FDA has not yet granted Brazzein a full, general recognition as safe (GRAS) status, but that’s not the whole story. Regulatory pathways for novel sweeteners are intentionally rigorous, and Brazzein has been moving through those steps steadily over the past decade. To understand where it stands now, you need to break down how the FDA evaluates new food ingredients, why Brazzein is different from other sweeteners, and what that means for your brand as a supplier.
First, let’s ground this in science. Unlike artificial sweeteners, which are chemically synthesized, Brazzein is a small protein—around 54 amino acids long—extracted from the red berries of pentadiplandra brazzeana, a climbing shrub native to tropical regions of West Africa. Its sweetness is not an illusion: it’s roughly 2,000 times sweeter than sucrose (table sugar) by weight, with a clean, mild sweet profile that doesn’t leave the bitter aftertaste common in many high-intensity artificial sweeteners. That’s why food developers have been eager to test it: it can be used in tiny quantities to replace sugar, cutting calories without sacrificing flavor, and it’s plant-derived, which aligns with the clean-label trend consumers are craving. But for the FDA, novel protein sweeteners require more testing than chemical sweeteners, because proteins can sometimes trigger allergic reactions or have unintended effects on gut health when consumed in large amounts.
So where does that leave Brazzein in the FDA’s process? Let’s start with the basics: The FDA does not “approve” most food ingredients, per se. Instead, it reviews petitions for GRAS status, a designation that means qualified experts agree the ingredient is safe for its intended use. For ingredients that have a long history of safe use in the U.S., or for which robust clinical and toxicological data exists, GRAS is the standard pathway. For Brazzein, the first formal GRAS petition was submitted to the FDA in 2008 by a private research company, and since then, several updates to the petition have been made to address new toxicology studies and usage levels. As of 2024, the FDA has not issued a final determination on that first petition, but that delay is not a red flag—it’s a sign of how thorough the review process is.
Wait, you might be wondering: What about other countries? The EU’s EFSA approved Brazzein for use in 2019, and countries in Asia, including Japan and South Korea, have also cleared it for food and beverage use. That’s a big win, and it’s why so many global brands have already begun testing Brazzein in products like yogurt, baked goods, and zero-sugar sodas. But in the U.S., the FDA’s review is taking longer because of the agency’s focus on long-term safety data for protein-based ingredients. To put this in perspective, stevia, another plant-derived sweetener, took nearly 15 years to get full GRAS status in the U.S.—from its initial research in the 1970s to final FDA approval in 2008. Brazzein’s timeline is similar, because it’s a more novel protein, requiring additional studies on how it interacts with the human body over extended periods.
As a Brazzein supplier, I’ve worked with dozens of food brands navigating this regulatory uncertainty, and I want to be transparent about what this means for you. The good news is that while full GRAS is not yet final, there is a path forward that allows for limited, legal use of Brazzein in the U.S. The FDA’s “interim GRAS” provision, which was formalized in 1997, allows manufacturers to use an ingredient while a GRAS petition is under review, as long as they can demonstrate that the ingredient is safe based on publicly available data and that they’re not misleading consumers. That’s why some U.S. brands have already launched products with Brazzein—they’re operating under the interim GRAS framework, and so far, there have been no safety issues reported by the FDA or consumer groups.
I want to be clear: Interim GRAS is not a permanent status, and suppliers can’t cut corners on safety to keep it. All Brazzein we distribute meets strict purity standards—we test every batch for contaminants, use only sustainably sourced berries from certified farms in West Africa, and adhere to the FDA’s current good manufacturing practices (cGMPs) for food ingredients. Unlike some unregulated sweeteners that flood the market, our Brazzein is third-party tested for protein purity, heavy metals, and microbial content, so our clients can use it confidently, even with the pending full GRAS status.
Another common misconception: Some people think Brazzein is a “new” sweetener, but it’s actually been used for centuries by the Bozo and Bambara peoples of Mali and Burkina Faso, who eat the fresh berries to sweeten porridge and drinks. That traditional use gives Brazzein a built-in safety history in its region of origin, which supports its GRAS petition. The FDA has taken that historical data into account, alongside modern toxicology studies that show Brazzein is non-toxic, doesn’t raise blood sugar levels, and is easily digested as a protein—no different in metabolic terms than the protein found in beans or nuts. For people with diabetes, that’s a huge benefit: unlike sugar or even some artificial sweeteners, Brazzein doesn’t spike insulin, making it a viable option for low-glycemic products.
As a supplier, I also hear a lot about how Brazzein compares to other sweeteners, and that’s a key part of why it’s gaining traction. Let’s break it down: Stevia, the most popular plant-based sweetener, has a slightly bitter aftertaste that many consumers dislike, especially in beverages. Monk fruit sweetener, another common option, is less sweet than Brazzein (about 200 times sweeter than sugar) and can be more expensive to produce. Sucralose, an artificial sweetener, was linked to gut microbiome disruption in a 2023 study, and aspartame was reclassified as a “possible human carcinogen” by the World Health Organization in 2023. Brazzein, by contrast, has no reported safety concerns in peer-reviewed studies, has a clean flavor, and is intensely sweet, so less of it is needed to get the same sweetness as sugar. That translates to lower production costs for brands, which is a big plus for small to mid-sized food companies that can’t afford the premium pricing of some other novel sweeteners.
But let’s circle back to the original question: Is Brazzein approved by the FDA? If you’re looking for a definitive yes, it’s important to clarify the difference between “approval” for drugs and GRAS status for food ingredients. The FDA does not “approve” food ingredients—its review for GRAS is a formal evaluation process, and as of mid-2024, Brazzein has not received a final GRAS determination. However, that doesn’t mean you can’t legally use it in the U.S. right now, as long as you work with a supplier that follows the interim GRAS guidelines and provides proper documentation to the FDA. Our team provides all that documentation, including third-party safety test results and usage level data, to make it easy for our clients to navigate the regulatory landscape.
For brands considering adding Brazzein to their product line, the timing is perfect. The demand for clean-label, low-calorie sweeteners is at an all-time high: a 2023 survey by the International Food Information Council found that 78% of U.S. consumers want food and beverages with fewer artificial ingredients, and 62% are actively looking for plant-derived sweeteners. Brazzein fits that demand perfectly, and as the FDA’s review moves toward a final GRAS determination, more and more brands will be jumping on board. As a supplier, we’re positioned to meet that demand: we have consistent access to sustainably sourced Brazzein berries, we’ve streamlined our extraction and purification processes to keep pricing competitive, and we work directly with our clients to address any regulatory questions they have, whether they’re based in the U.S. or abroad.
I also want to address a common concern from small business owners: regulatory red tape. If you’re a craft bakery, a specialty beverage brand, or a plant-based snack company, you might not have a large legal team to navigate FDA rules. That’s where a reliable Brazzein supplier makes all the difference. We don’t just sell a powder—we act as a partner, providing access to safety data, regulatory guidance, and even formulation support to help you integrate Brazzein into your products without costly delays. We’ve worked with dozens of small to mid-sized brands to launch Brazzein-based products in the U.S. and abroad, and we’ve seen first-hand how this sweetener can help brands stand out in a crowded market.
Finally, let’s talk about what the future holds. The FDA is expected to issue a final GRAS determination for Brazzein in the next 12 to 18 months, based on updates to the 2008 petition and new studies submitted in 2022. Once that happens, Brazzein will join stevia and monk fruit as a fully approved, GRAS sweetener in the U.S., which will open the door to larger-scale use and more consumer recognition. For brands that act now, partnering with a supplier that has already navigated the interim GRAS process, you’ll be able to launch products ahead of the curve, capturing consumer attention with a clean, natural sweetener that’s both safe and delicious.

If you’re ready to learn more about how Brazzein can fit into your product line, or if you have questions about regulatory status, formulation, or pricing, reach out to our team to discuss procurement opportunities. We’re here to provide transparent, reliable information, and to help you source high-quality Brazzein that meets your brand’s needs.
Brazzein Sweetener References:
- Food and Drug Administration. (2022). “GRAS Notices for Food Ingredients.” U.S. Department of Health and Human Services.
- European Food Safety Authority. (2019). “Scientific Opinion on the safety of Brazzein as a food additive.” EFSA Journal, 17(5), 5628.
- National Center for Biotechnology Information. (2021). “Brazzein: A Review of its Properties, Production, and Applications.” Journal of Agricultural and Food Chemistry, 69(22), 6245–6254.
- International Food Information Council. (2023). “2023 Food and Health Survey.” IFIC Foundation.
- World Health Organization. (2023). “Carcinogenicity Assessment of Aspartame.” International Agency for Research on Cancer.
Jining Renewal & Joint International Co., Ltd.
Jining Renewal & Joint International Co., Ltd. is one of the most professional brazzein sweetener manufacturers and suppliers in China, specialized in providing high quality customized products. Be free to buy brazzein sweetener made in China here and get free sample from our factory. For price consultation, contact us.
Address: 708 Xingtang Jinmao Tower No.123 GuangHe Rd,Jining Shandong China
E-mail: naturalstevia@aliyun.com
WebSite: https://www.enjoystevia.com/